<DOC>
	<DOCNO>NCT02617004</DOCNO>
	<brief_summary>The purpose study prospectively validate new risk model , base minimal residual disease ( MRD ) response level oncogenetic status compare historical result GRAALL-2005 GRAALL-2014 identical population patient ( Philadelphia chromosome negative , B lineage ALL , age 18 59 year old ) .</brief_summary>
	<brief_title>Multicenter Trial Treatment Philadelphia Chromosome Negative B-cell Acute Lymphoblastic Leukemia Young Adults</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<criteria>1 . Whose blood bone marrow exploration complete steroid prephase 2 . Aged 18 59 year old previously treat ( include intrathecal injection ) BlineageALL newly diagnose accord WHO 2008 definition ≥ 20 % bone marrow blast 3 . Whose karyotype show ( 9 ; 22 ) and/or absence molecular biology breakpoint cluster regionAbelson ( BCRABL ) 4 . With Eastern Cooperative Oncology Group ( ECOG ) performance status ≤3 5 . With without central nervous system ( CNS ) testis involvement 6 . Without evolve cancer ( except basal cell carcinoma skin `` situ '' carcinoma cervix ) radiotherapy chemotherapy treatment finish least since 6 month 7 . Having sign write informed consent 8 . With efficient contraception woman childbearing age ( exclude estrogen IUD ) 9 . With health insurance coverage 10. Who receive receive steroid prephase 1 . With lymphoblastic lymphoma bone marrow blast &lt; 20 % , Burkitttype ALL , antecedents chronic myeloid leukemia ( CML ) myeloproliferative neoplasm 2 . With contraindication anthracyclines general visceral contraindication intensive therapy except consider related ALL : Aspartate transaminase ( AST ) and/or alanine transaminase ( ALT ) &gt; 5 x upper limit normal range ( ULN ) Total bilirubin ≥ 2.5 x upper limit normal range ( ULN ) Creatinine &gt; 1.5x upper limit normal range ( ULN ) creatinine clearance &lt; 50 mL/mn 3 . Myocardial infarction within 6 month prior inclusion trial , cardiomyopathy ( NYHA grade III IV ) , leave ventricle ejection fraction ( LVEF ) &lt; 50 % Shortening fraction &lt; 30 % , 4 . Active severe infection know seropositivity HIV human T cell leukemia/lymphoma virus type 1 ( HTLV1 ) active hepatitis B C 5 . Pregnant ( betaHuman Chorionic Gonadotropin positive ) nurse woman 6 . Not able bear procedure frequency visit plan trial 7 . Unable consent , tutelage curator , judiciary safeguard .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>